The performance of the associated company was a drag, and pharmaceutical giant Sino Biopharmaceutical warned that the net profit in the first half of the year fell 78% compared with the same period last year.

Breakings · Aug 12, 2022 01:14

Sino Biopharmaceutical warned that in the first half of this year, due to the lower financial performance of an associated company than in the same period last year, the profits attributable to the holders of the group's parent company decreased by as much as 78 per cent to about 1.871 billion yuan compared with the same period last year. Details are to be disclosed in the interim results announcement to be issued on August 23. Many analyses point to Sinopec, which significantly increased Sino Biopharmaceutical's profits last year.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

联营公司业绩拖累，药企巨头中国生物制药预警上半年净利同比降78%

The performance of the associated company was a drag, and pharmaceutical giant Sino Biopharmaceutical warned that the net profit in the first half of the year fell 78% compared with the same period last year.

Risk Disclaimer

Statement